

April 1, 2022

BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, <u>MUMBAI - 400 001</u>.

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051.

Dear Sir/Madam,

<u>Re: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations</u> and Disclosure Requirements) Regulations, 2015.

Sub: Acquisition of portfolio of brands from Anglo-French Drugs & Industries Limited.

In furtherance to our intimation to your Exchange on January 18, 2022, we are pleased to inform you that the Company has signed Definitive Agreement with Anglo-French Drugs & Industries Limited for acquiring a portfolio of brands (including all rights and interests associated with such products), to strengthen the Company's presence in Vitamins, Minerals & Supplements and CNS segments.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

R. V. SATAM COMPANY SECRETARY (ACS - 11973)